A Multicentre, Non-interventional Post Marketing Study of Safety and Efficacy of NovoEight (rFVIII) During Long-Term Treatment of Haemophilia A in Japan
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Jun 2019
Price : $35 *
At a glance
- Drugs Turoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 05 Jun 2019 Planned number of patients changed from 35 to 40.
- 05 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 10 Aug 2018 Planned End Date changed from 4 Aug 2020 to 4 Feb 2021.